Cohance Lifesciences: Promoters Declare No New Share Encumbrances
Cohance Lifesciences promoters, Berhyanda Limited and associated entities, declared on April 7, 2026, that no new share encumbrances have been made. This declaration is in compliance with SEBI Takeover Regulations, confirming no additional pledges beyond those disclosed in FY2025-26.
This is a routine disclosure as per SEBI regulations, confirming the status quo regarding share encumbrances by promoters. It does not introduce new information that would significantly impact the company's valuation or operations.
The announcement is a routine regulatory filing confirming no new encumbrances, which does not inherently signal positive or negative news for the company's stock performance.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has received a declaration from its promoters, Berhyanda Limited, along with persons acting in concert: Jusmiral Holdings Limited, Berhyanda Midco Limited, and Jusmiral Midco Limited.
This declaration, made on April 7, 2026, is pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011. The promoters state that they have not made any encumbrance on the shares of Cohance Lifesciences Limited, directly or indirectly, beyond what was already disclosed during the financial year 2025-26.
The announcement was submitted to the BSE Limited and the National Stock Exchange of India Limited for their information and record.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.